1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Orchid Pharma Limited

Orchid Pharma Limited

823.30
INR
-52.25
(-5.97%)
1.52EPS
594.07P/E
49.34BMarket Cap
Nov 16Next Earn
Orchid Pharma Limited
NSE:ORCHPHARMA
(National Stock Exchange of India)

Recent

price

823.30

P/E

ratio

594.07

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
190.72
252.94
254.44
174.3
- -
100.25
89.53
76.77
67.43
54.46
110.26
137.09
163.14
169.35
231.89
203.25
178.08
Revenue per Share
48.16
22.17
13.84
-39.09
- -
-32.07
-55.69
-39.65
7.8
-14.75
-28.55
-0.48
11.35
19.06
22.55
1.66
1.64
Basic EPS, GAAP
-36.77
-7.75
62.89
- -
- -
24.21
44.09
0.33
0.61
8.62
5.63
19.13
-16.31
12.65
-17.07
-44.08
- -
Free Cash Flow per Basic Share
1.17
11.61
3.54
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
133.11
151.79
167.59
- -
38.63
-2.65
-52.46
-89
-79.14
187.67
159.96
158.61
168.72
230.58
306.38
308.43
- -
Book Value per Share
115.63
143.1
142.26
- -
23.25
-18.31
-67.62
-103.86
-93.75
181.6
159.87
158.53
168.62
227.64
303.03
293.9
- -
Tangible Book Value per Share
70
70
70
70
73
87
89
89
89
89
41
41
41
48
60
60
53
Basic Weighted Avg Shares
13,435
17,818
17,923
12,279
- -
8,725
7,965
6,830
6,000
4,838
4,501
5,596
6,659
8,191
13,887
12,172
9,426
Sales/Revenue/Turnover
53.01
12.08
13.14
-2
- -
2.92
-13.72
-13.1
-12.28
-14.49
-11.03
-5.8
4.46
9.58
9.01
3.35
8.5
Operating Margin (%)
1,549
1,335
1,537
1,572
- -
1,453
1,411
1,333
1,299
1,179
1,089
870
548
332
420
432
377
Depreciation Expense
3,393
1,562
975
-2,754
- -
-2,791
-4,954
-3,528
694
-1,311
-1,165
-20
463
922
1,351
100
87
Net Income, GAAP
27.79
8.96
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.74
Effective Tax Rate (%)
25.25
8.77
5.44
-22.43
- -
-31.99
-62.2
-51.65
11.57
-27.09
-25.89
-0.35
6.96
11.25
9.73
0.82
0.92
Profit Margin (%)
7,287
-4,631
-1,644
- -
1,555
-3,264
-8,351
-13,336
-15,781
3,944
4,078
1,569
1,291
5,308
5,888
4,381
- -
Working Capital
10,359
6,041
10,741
- -
24,940
23,775
21,568
18,939
14,246
5,040
4,275
2,082
1,488
1,208
101
1,895
- -
LT Debt
9,377
10,712
11,834
- -
3,294
-236
-4,667
-7,918
-7,040
7,660
6,529
6,474
6,886
11,695
15,539
15,643
- -
Total Equity
23.21
9.47
- -
- -
- -
- -
- -
- -
5.22
- -
- -
- -
7.53
- -
- -
- -
- -
Return on Invested Capital (%)
15.31
12.68
- -
- -
- -
- -
- -
- -
2.82
- -
- -
- -
8.12
- -
- -
- -
- -
Return on Capital (%)
43.18
15.56
8.67
- -
- -
- -
- -
- -
- -
- -
-16.43
-0.3
6.93
9.92
9.92
0.64
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
1,171
- -
LT Borrowings
- -
1,847
- -
LT Finance Leases
- -
47
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
51
51
51
Market Capitalization
38,493
24,469
49,340

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
9,293
- -
Cash, Cash Equivalents & STI
- -
841
- -
Accounts Receivable, Net
- -
3,814
- -
Inventories
- -
3,723
- -
Total Current Liabilities
- -
4,912
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
1,171
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
182.55%
21.78%
0.67%
Free Cash Flow
107.07%
-49.26%
158.24%
Net Income, GAAP
-289.02%
-503.85%
-92.63%
Sales/Revenue/Turnover
6.21%
24.71%
-12.35%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
2,444
2,227
2,173
2,375
13,887
2026
2,632
1,935
2,073
2,376
12,172
2027
3,042
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
5.79
5.37
4.1
4.4
22.55
2026
-0.95
-1.13
-2.49
4.69
1.66
2027
0.54
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Orchid Pharma Limited, founded in 1992 and headquartered in Chennai, India, develops, manufactures and markets active pharmaceutical ingredients, primarily cephalosporin antibiotics across all five generations, and finished dosage forms including oral solids, injectables and suspensions for human and veterinary use; it operates as a vertically integrated export-oriented unit with facilities in Tamil Nadu and Jammu, serving regulated markets in the United States, Europe and other regions through a global customer base that includes pharmaceutical companies and healthcare institutions. The company specializes in anti-infectives targeting infections such as urinary tract infections, pneumonia, skin infections and multi-drug resistant bacteria, with key products encompassing sterile cephalosporins, beta-lactam APIs, key starting materials like 7-ACA, and innovative therapies including the novel chemical entity Enmetazobactam combined with Cefepime (marketed as EXBLIFEP globally and Orblicef in India), which received USFDA, EMA and DCGI approvals for treating complicated infections. Orchid Pharma, a subsidiary of Dhanuka Laboratories Limited, maintains USFDA, MHRA, EDQM and GMP certifications, invests significantly in R&D (approximately 6-10% of revenue), and generates the majority of its sales from cephalosporin APIs supplemented by formulations and contract services. Recent developments include the acquisition of full global rights to Enmetazobactam from Allecra Therapeutics' assets in 2024-2025 following partner insolvency, enabling worldwide licensing and direct commercialization; the launch of the Orchid Anti-Microbial Stewardship division targeting Rs 250-300 crore revenue through hospital collaborations; NCLT approval of the first motion for merging Dhanuka Laboratories to create a combined entity with over Rs 1,500 crore revenue; Rs 600 crore greenfield investment under the PLI scheme for a 7-ACA facility in Jammu; Rs 150 crore state-of-the-art injectables facility in partnership with GARDP; capacity expansions in oral APIs; and USFDA issuance of a Voluntary Action Indicated status post-inspection in 2025.